Regeneron Pharmaceuticals — Jul 30, 2026 release

In July 2026, the Company's board of directors declared a cash dividend of $0.94 per share on the Company's common stock and Class A stock, payable on August 31, 2026 to shareholders of record as of August 18, 2026. 2026 Financial Guidance* The Company's full year 2026 financial guidance consists of the following components: 2026 Guidance Prior Updated GAAP R&D $6.450–$6.680 billion $6.500–$6.635 billion Non-GAAP R&D (a) $5.900–$6.100 billion $5.950–$6.050 billion GAAP SG&A $2.860–$3.040 billion $2.830–$2.960 billion Non-GAAP SG&A (a) $2.500–$2.650 billion $2.500–$2.600 billion GAAP gross margin on net product sales 77%–78% 78%–79% Non-GAAP gross margin on net product sales (a) 83%–84% 84%–85% GAAP COCM $955 million–$1.035 billion $985 million–$1.035 billion Non-GAAP COCM (a) $940 million–$1.020 billion $970 million–$1.020 billion Capital expenditures $1.100–$1.200 billion $1.030–$1.100 billion GAAP effective tax rate 12%–14% 13%–14% Non-GAAP effective tax rate (a) 13%–15% 14%–15% * The Company's 2026 financial guidance does not assume the completion of any business development transactions not completed as of the date of this press release 5 A reconciliation of full year 2026 GAAP to non-GAAP financial guidance is included below: Projected Range ($ in millions) Low High GAAP R&D $ 6,500  $ 6,635  Stock-based compensation expense (550) (580) Other — (5) Non-GAAP R&D (a) $ 5,950  $ 6,050  GAAP SG&A $ 2,830  $ 2,960  Stock-based compensation expense (330) (350) Other* —  (10) Non-GAAP SG&A (a) $ 2,500  $ 2,600  GAAP gross margin on net product sales 78% 79% Stock-based compensation